Related Experiment Video
Updated: Jul 6, 2026
05:34
5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
Adynamic bone in patients with chronic kidney disease
1Division of Nephrology, University of Washington, Seattle, Washington, USA. dennis.andress@abbott.com
Kidney International
|March 14, 2008
Summary
Adynamic bone disease in chronic kidney disease (CKD) patients increases fracture and cardiovascular disease (CVD) risks. Vitamin D receptor activators (VDRAs) may prevent bone loss and reduce CVD, warranting further cardiovascular outcome studies.
Area of Science:
- Nephrology
- Endocrinology
- Bone Metabolism
Background:
- Adynamic bone disease (ABD) is a concern in chronic kidney disease (CKD) due to elevated fracture and cardiovascular disease (CVD) risks.
- Prevalence of ABD varies significantly, often linked to classification and population differences, particularly in elderly patients with diabetes and comorbidities.
- Vitamin D deficiency is common in CKD, leading to decreased levels of active 1,25-dihydroxyvitamin D.
Purpose of the Study:
- To review the clinical significance of adynamic bone in CKD patients.
- To discuss the role of vitamin D receptor activators (VDRAs) in managing bone and cardiovascular health in CKD.
- To highlight the need for further research on VDRA safety and efficacy regarding cardiovascular outcomes.
Main Methods:
- Literature review on adynamic bone disease in CKD.
- Analysis of the impact of vitamin D deficiency and VDRA therapy.
- Discussion of prevalence, risk factors, and therapeutic considerations.
Main Results:
- Adynamic bone is associated with increased fracture and CVD risk in CKD.
- Vitamin D receptor activators (VDRAs) show potential in preventing bone loss and reducing CVD morbidity.
- VDRAs may stimulate bone formation and are considered essential regardless of bone turnover status.
Conclusions:
- Vitamin D receptor activators (VDRAs) offer a promising therapeutic option for CKD patients with adynamic bone disease.
- Further studies are crucial to evaluate the cardiovascular risk/benefit profile of VDRAs in CKD.
- VDRAs should be considered essential therapy for CKD patients, irrespective of their bone turnover status.
More Related Videos
Related Concept Videos
01:24Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
01:28Chronic Kidney Disease III: Interprofessional Care
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
01:29Bone Disorders
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
01:25Chronic Kidney Disease I: Introduction
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
01:02What is the Skeletal System?
Overview
01:18Chronic Kidney Disease IV: Nursing Management
Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of fluid...